ART Advanced Research Technologies Inc. Announces Unanimous Support in Favour of Its Proposal to Creditors

ART Advanced Research Technologies Inc. (ART) (TSX:ARA), a Canadian medical
device company and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, announces that its unsecured creditors

(the "Unsecured Creditors") voted unanimously in support of its proposal (the
"Proposal") under the Bankruptcy and Insolvency Act (the "BIA"), as amended, at
a meeting of Unsecured Creditors held today (the "Meeting").


Following the filing of an amended Proposal at the Meeting, the terms of which
do not affect the distribution of the $375,000 available to ART's Unsecured
Creditors, the Unsecured Creditors of ART voted in favor of the amended
Proposal, with 100% of the votes cast supporting the Proposal.


ART is scheduled to seek court approval of the amended Proposal on December 9, 2009.

This announcement follows the announcement made on November 20, 2009 that ART
entered on that day into an agreement today with Dorsky Worldwide Corp. to
restructure ART's balance sheet and share capital and position it to continue in
business. As contemplated in that agreement, ART filed on November 23, 2009 its
Proposal to its Unsecured Creditors under the BIA through KPMG Inc.


About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging
products for the healthcare and pharmaceutical industries. ART has developed
products in medical imaging, medical diagnostics, disease research, and drug
discovery with the goal of bringing new and better treatments to patients
faster. The Optix(R) optical molecular imaging system, designed for monitoring
physiological changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The SoftScan(R)
optical medical imaging device is designed to improve the diagnosis and
treatment of breast cancer. Finally, the Fenestra(R) line of molecular imaging
contrast products provides image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in their imaging
studies, with potential extension into other major imaging modalities. ART is
commercializing some of these products in a global strategic alliance with GE
Healthcare, a world leader in mammography and imaging. ART's shares are listed
on the TSX under the ticker symbol ARA. For more information on ART and its
restructuring, visit our website at www.art.ca


This press release may contain forward-looking statements subject to risks and
uncertainties that would cause actual events to differ materially from
expectations. These risks and uncertainties are described in the most recent
Annual Information Form and the financial statements for the year ended December
31, 2008, available on SEDAR (www.sedar.com).